Please use this identifier to cite or link to this item:
https://repository.iimb.ac.in/handle/2074/11293
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Branstetter, Lee | - |
dc.contributor.author | Chatterjee, Chirantan | - |
dc.contributor.author | Higgins, Matthew J | - |
dc.date.accessioned | 2020-04-02T13:02:43Z | - |
dc.date.available | 2020-04-02T13:02:43Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0741-6261 | - |
dc.identifier.uri | https://repository.iimb.ac.in/handle/2074/11293 | - |
dc.description.abstract | We thank Tamer Abdelgawad, Serguey Braguinsky, Iain Cockburn, Marty Gaynor, David Greenstreet, Bart Hamilton, Lowell Taylor, Jerry Thursby, Kenneth Train, Scott Stern, Dietmar Harhoff, Carolin Haeussler, Murray Aitken, Kensuke Kubo, Vineet Kumar, Jian Ni, and Ellerie Weber, as well as seminar participants at Emory, Cornell, Carnegie Mellon, IIM Bangalore, IIM Ahmedabad, Passau, Charles River Associates, Precision Health Economics, and the NBER Summer Institute (Cambridge, 2011) for valuable comments and discussions. We thank Bhaven Sampat for helpful comments and for sharing patent data. We are grateful to Judith Chevalier and two anonymous referees for detailed comments and suggestions that significantly improved an earlier draft. We thank Susan Jack, Margaret Warner, and Robert Anderson for guidance in using the National Health Interview Survey, and we thank Antara Dutta for sharing her code with us as well as for extensive discussions. Programming assistance by Avadhoot Jathar, Nachiket Sahoo, Anubrata Banerjee, and Trupti Natu is appreciated. We are grateful for the time Dr. Terry Simon and Dr. Ronald Severtis spent explaining to us the treatment of hypertension. We also thank Murray Aitken and IMS Health Incorporated for their generous support and access to their data. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities. The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IMS Health Incorporated or affiliate information service(s): IMS Midas™, IMS Lifecycle™, IMS National Disease and Therapeutic Index™, IMS National Prescription Audit™, January 2000 to December 2008, IMS Health Incorporated or its affiliates. All Rights Reserved. Higgins acknowledges funding from The Imlay Professorship and Pfizer, Inc. Chatterjee and Branstetter acknowledge funding from NSF SCISIP grant no. #0830233 and from the Young Faculty Research Chair at IIM Bangalore. Authors are listed alphabetically and the usual disclaimers apply. | - |
dc.publisher | Wiley-Blackwell Publishing, Inc. | - |
dc.subject | Pharmaceutical industry | - |
dc.subject | Regulation and welfare | - |
dc.title | Regulation and welfare: Evidence from paragraph IV generic entry in the pharmaceutical industry | - |
dc.type | Journal Article | - |
dc.identifier.doi | 10.1111/1756-2171.12157 | - |
dc.pages | 857-890p. | - |
dc.vol.no | Vol.47 | - |
dc.issue.no | Iss.4 | - |
dc.journal.name | Rand Journal of Economics | - |
Appears in Collections: | 2010-2019 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.